JP2019529419A5 - - Google Patents

Info

Publication number

JP2019529419A5

JP2019529419A5 JP2019514769A JP2019514769A JP2019529419A5 JP 2019529419 A5 JP2019529419 A5 JP 2019529419A5 JP 2019514769 A JP2019514769 A JP 2019514769A JP 2019514769 A JP2019514769 A JP 2019514769A JP 2019529419 A5 JP2019529419 A5 JP 2019529419A5

Authority

JP

Japan

Prior art keywords

alkyl

aryl

heterocyclyl

heteroaryl

use according

Prior art date

2017-09-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 125000000217 alkyl group Chemical group 0.000 claims 20
• 125000000623 heterocyclic group Chemical group 0.000 claims 19
• 125000003118 aryl group Chemical group 0.000 claims 18
• 125000001072 heteroaryl group Chemical group 0.000 claims 15
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 14
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 13
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 13
• 229910052739 hydrogen Inorganic materials 0.000 claims 12
• 239000001257 hydrogen Substances 0.000 claims 12
• 125000005843 halogen group Chemical group 0.000 claims 11
• 125000003710 aryl alkyl group Chemical group 0.000 claims 9
• 125000001424 substituent group Chemical group 0.000 claims 8
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 5
• 150000001345 alkine derivatives Chemical class 0.000 claims 5
• 150000001875 compounds Chemical class 0.000 claims 5
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 5
• 229940124291 BTK inhibitor Drugs 0.000 claims 4
• 125000004093 cyano group Chemical group *C#N 0.000 claims 4
• 150000002431 hydrogen Chemical class 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 4
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
• 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
• 229940002612 prodrug Drugs 0.000 claims 4
• 239000000651 prodrug Substances 0.000 claims 4
• 150000003839 salts Chemical class 0.000 claims 4
• 239000012453 solvate Substances 0.000 claims 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
• -1 heteroalkenylene Chemical group 0.000 claims 3
• RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 claims 2
• 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 2
• VVLHQJDAUIPZFH-UHFFFAOYSA-N 4-[4-[[5-fluoro-4-[3-(prop-2-enoylamino)anilino]pyrimidin-2-yl]amino]phenoxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC=3N=C(NC=4C=C(NC(=O)C=C)C=CC=4)C(F)=CN=3)=CC=2)=C1 VVLHQJDAUIPZFH-UHFFFAOYSA-N 0.000 claims 2
• DNVXATUJJDPFDM-KRWDZBQOSA-N JQ1 Chemical compound N([C@@H](CC(=O)OC(C)(C)C)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 DNVXATUJJDPFDM-KRWDZBQOSA-N 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 125000004432 carbon atom Chemical group C* 0.000 claims 2
• 125000004474 heteroalkylene group Chemical group 0.000 claims 2
• 125000004043 oxo group Chemical group O=* 0.000 claims 2
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
• 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
• AAAQFGUYHFJNHI-SFHVURJKSA-N 2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(OC)C=C11)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 AAAQFGUYHFJNHI-SFHVURJKSA-N 0.000 claims 1
• TXZPMHLMPKIUGK-UHFFFAOYSA-N 2-methoxy-N-(3-methyl-2-oxo-1,4-dihydroquinazolin-6-yl)benzenesulfonamide Chemical compound COC1=CC=CC=C1S(=O)(=O)NC1=CC=C(NC(=O)N(C)C2)C2=C1 TXZPMHLMPKIUGK-UHFFFAOYSA-N 0.000 claims 1
• JIFCFQDXHMUPGP-UHFFFAOYSA-N 4-tert-butyl-n-[2-methyl-3-[4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxopyrazin-2-yl]phenyl]benzamide Chemical compound C1=CC=C(C=2N=C(NC=3C=CC(=CC=3)C(=O)N3CCOCC3)C(=O)N(C)C=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 JIFCFQDXHMUPGP-UHFFFAOYSA-N 0.000 claims 1
• SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 claims 1
• ZTUJNJAKTLHBEX-UHFFFAOYSA-N 6-cyclopropyl-8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-6-oxopyridin-3-yl]phenyl]isoquinolin-1-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C(=C(C=CC=2)N2C(C3=C(F)C=C(C=C3C=C2)C2CC2)=O)CO)=CN(C)C1=O ZTUJNJAKTLHBEX-UHFFFAOYSA-N 0.000 claims 1
• VUVUVNZRUGEAHB-CYBMUJFWSA-N 7-(3,5-dimethyl-4-isoxazolyl)-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-3H-imidazo[4,5-c]quinolin-2-one Chemical compound C1([C@@H](C)N2C3=C4C=C(C(=CC4=NC=C3NC2=O)C2=C(ON=C2C)C)OC)=CC=CC=N1 VUVUVNZRUGEAHB-CYBMUJFWSA-N 0.000 claims 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
• 239000012664 BCL-2-inhibitor Substances 0.000 claims 1
• 229940123711 Bcl2 inhibitor Drugs 0.000 claims 1
• 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 1
• 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 1
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
• UVSVTDVJQAJIFG-VURMDHGXSA-N LFM-A13 Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC(Br)=CC=C1Br UVSVTDVJQAJIFG-VURMDHGXSA-N 0.000 claims 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
• WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 claims 1
• 125000003342 alkenyl group Chemical group 0.000 claims 1
• 125000004450 alkenylene group Chemical group 0.000 claims 1
• 125000002947 alkylene group Chemical group 0.000 claims 1
• 125000000304 alkynyl group Chemical group 0.000 claims 1
• NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 claims 1
• 210000003719 b-lymphocyte Anatomy 0.000 claims 1
• ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 claims 1
• 229910052799 carbon Inorganic materials 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
• 125000000753 cycloalkyl group Chemical group 0.000 claims 1
• 210000001102 germinal center b cell Anatomy 0.000 claims 1
• 125000005842 heteroatom Chemical group 0.000 claims 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
• 229960001507 ibrutinib Drugs 0.000 claims 1
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 230000000155 isotopic effect Effects 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
• 229910052757 nitrogen Inorganic materials 0.000 claims 1
• GCWIQUVXWZWCLE-INIZCTEOSA-N pelabresib Chemical compound N([C@@H](CC(N)=O)C=1ON=C(C=1C1=CC=CC=C11)C)=C1C1=CC=C(Cl)C=C1 GCWIQUVXWZWCLE-INIZCTEOSA-N 0.000 claims 1
• 238000006467 substitution reaction Methods 0.000 claims 1
• GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1